Companies: 48,874 Total Market Cap: 132277928135933.45

Celltrion

KRX-068270
Healthcare Biotechnology
Rank #905
Market Cap 23.31 B
Volume 416,637
Price 109.34
Change (%) 0.33%
Country or region South Korea South Korea

Celltrion's latest marketcap:

23.31 B

As of 05/17/2025, Celltrion's market capitalization has reached $23.31 B. According to our data, Celltrion is the 905th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 23.31 B
Revenue (ttm) 2.53 B
Net Income (ttm) 300.11 M
Shares Out 213.20 M
EPS (ttm) 1.38
Forward PE 34.62
Ex-Dividend Date 12/27/2024
Earnings Date 05/09/2025
Market Cap Chart
Data Updated: 05/17/2025

Celltrion's yearly market capitalization.

Celltrion has seen its market value drop from ₩48,989.35 B to ₩32,832.24 B since 2020, representing a total decrease of 32.98% and an annual compound decline rate (CAGR) of 8.73%.
Date Market Cap Change (%)
05/17/2025 ₩32,832.24 B -15.34%
12/30/2024 ₩40,365.45 B 44.32%
12/28/2023 ₩27,970.38 B 21.61%
12/29/2022 ₩23,000.36 B -16.64%
12/30/2021 ₩27,592.58 B -43.68%
12/30/2020 ₩48,989.35 B

Company Profile

About Celltrion, Inc.

Celltrion, Inc., together with its subsidiaries, develops and produces protein-based drugs for oncology treatments in South Korea. The company operates in the biopharmaceutical sector, focusing on innovative therapies and diagnostics.

Product Offerings

  • Bio Pharmaceuticals: Specialized treatments for various medical conditions.
  • Generic Pharmaceuticals: Affordable alternatives to branded medications.
  • COVID-19 Test Kits: Diagnostic solutions for pandemic response.

Pipeline Highlights

The company's antibody biosimilar pipeline includes several advanced-stage candidates:

  • CT-P39: Phase 3 clinical trial for asthma and urticaria.
  • CT-P41: Phase 3 clinical trial for osteoporosis and bone loss.
  • CT-P42: Phase 3 clinical trial for diabetic macular edema.
  • CT-P43: Phase 3 clinical trial for psoriasis, Crohn's disease, and ulcerative colitis.
  • CT-P47: Phase 3 clinical trial for rheumatoid arthritis.
  • CT-P53: Phase 3 clinical trial for multiple sclerosis.

Company Background

Founded in 2002, Celltrion, Inc. is headquartered in Incheon, South Korea, and continues to drive advancements in biopharmaceutical research and development.

Frequently Asked Questions

As of 05/17/2025, Celltrion (including the parent company, if applicable) has an estimated market capitalization of $23.31 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Celltrion global market capitalization ranking is approximately 905 as of 05/17/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region South Korea
Founded 2002
IPO Date n/a
Employees 2,391
CEO
Sector Healthcare
Industry Biotechnology
Address 23 Academy-ro
Incheon
South Korea
Website https://www.celltrion.com
People Also Watch
VRTX
438.65 0.33%
CSL Limited
154.76 0.33%
REGN
594.32 0.33%
KRX-207940
708.58 0.33%